Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Next Previous
X
Search
Trial Profile

Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRE-1
  • Sponsors Pfizer

    • Most Recent Events

    • 28 Aug 2023 Results (n=190) assessing the potential anti-inflammatory effects of PCSK9 inhibition using plasma proteomics from SPIRE-1/2 trials, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
    • 08 Jan 2021 Results from CANTOS, JUPITER, SPIRE-1, SPIRE-2, and CIRT trials published in the European Heart Journal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top